nach oben

The Journal of Behavioral Health Services & Research

Erschienen in:

06.07.2023

Negative Urgency Linked to Craving and Substance Use Among Adults on Buprenorphine or Methadone

verfasst von: Stefanie F. Gonçalves, MA, Alyssa M. Izquierdo, MA, Rebecca A. Bates, DNP, FNP-C, PMP, Angeela Acharya, MS, Holly Matto, PhD, LCSW-C, Siddhartha Sikdar, PhD

Erschienen in: The Journal of Behavioral Health Services & Research | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Despite the effectiveness of medication-assisted treatment (MAT), adults receiving MAT experience opioid cravings and engage in non-opioid illicit substance use that increases the risk of relapse and overdose. The current study examines whether negative urgency, defined as the tendency to act impulsively in response to intense negative emotion, is a risk factor for opioid cravings and non-opioid illicit substance use. Fifty-eight adults (predominately White cis-gender females) receiving MAT (with buprenorphine or methadone) were recruited from online substance use forums and asked to complete self-report questionnaires on negative urgency (UPPS-P Impulsive Behavior Scale), past 3-month opioid cravings (ASSIST—Alcohol, Smoking, and Substance Involvement Screening Test), and non-opioid illicit substance use (e.g., amphetamines, cocaine, benzodiazepines). Results revealed that negative urgency was associated with past 3-month opioid cravings, as well as past month illicit stimulant use (not benzodiazepine use). These results may indicate that individuals high in negative urgency would benefit from receiving extra intervention during MAT.

Fairley M, Humphreys K, Joyce VR, et al. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiatry 2021;78(7):767-777. https://doi.org/10.1001/jamapsychiatry.2021.0247CrossRefPubMed

Klein AA, Seppala MD. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results. Journal of Substance Abuse Treatment 2019;104:51-63. https://doi.org/10.1016/j.jsat.2019.06.009CrossRefPubMed

Northrup TF, Stotts AL, Green C, et al. Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: A discrete survival and growth mixture model. Addictive Behaviors 2015;41:20-28. https://doi.org/10.1016/j.addbeh.2014.09.021CrossRefPubMed

Tsui JI, Anderson BJ, Strong DR, et al. Craving predicts opioid use in opioid-dependent patients initiating buprenorphine treatment: A longitudinal study. The American Journal of Drug and Alcohol Abuse 2014;40(2):163-169. https://doi.org/10.3109/00952990.2013.848875CrossRefPubMedPubMedCentral

Ferri M, Finlayson AJR, Wang L, et al. Predictive factors for relapse in patients on buprenorphine maintenance. The American Journal on Addictions 2013;23(1):62-67. https://doi.org/10.1111/j.1521-0391.2013.12074.xCrossRefPubMedPubMedCentral

Clark RE, Baxter JD, Aweh G, et al. Risk factors for relapse and higher costs among medicaid members with opioid dependence or abuse: Opioid agonists, comorbidities, and treatment history. Journal of Substance Abuse Treatment 2015;57:75-80. https://doi.org/10.1016/j.jsat.2015.05.001CrossRefPubMedPubMedCentral

Hedegaard H, Bastian BA, Trinidad JP, et al. Drugs most frequently involved in drug overdose deaths: United States, 2011–2016. National Vital Statistics Reports 2018;67(9):1-13. https://www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_09-508.pdf. Accessed 5 September 2022PubMed

Armoon B, SoleimanvandiAzar N, Rostami M, et al. Drug type and risk behaviors associated with non-fatal overdose among people who use drugs: a systematic review and meta-analysis. Journal of Addictive Diseases 2021;40(1):114-125. https://doi.org/10.1080/10550887.2021.1950262CrossRefPubMed

Whiteside SP, Lynam DR. The Five Factor Model and impulsivity: using a structural model of personality to understand impulsivity. Personality and Individual Differences 2001;30(4):669-689. https://doi.org/10.1016/s0191-8869(00)00064-7CrossRef

10.

Li J, Weidacker K, Mandali A, et al. Impulsivity and craving in participants with opioid use disorder on methadone maintenance treatment. Drug and Alcohol Dependence 2021;219:108483. https://doi.org/10.1016/j.drugalcdep.2020.108483CrossRefPubMed

11.

Wenzel KR, Weinstock J, Vander Wal JS, et al. Examining the role of negative urgency in a predictive model of bulimic symptoms. Eating Behaviors 2014;15(3):343-349. https://doi.org/10.1016/j.eatbeh.2014.04.014CrossRefPubMed

12.

Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. The American Journal of Psychiatry 1985;142(11):1259-1264. https://doi.org/10.1176/ajp.142.11.1259CrossRefPubMed

13.

Zorrilla EP, Koob GF. Impulsivity derived from the dark side: Neurocircuits that contribute to negative urgency. Frontiers in Behavioral Neuroscience 2019;13:136. https://doi.org/10.3389/fnbeh.2019.00136.CrossRefPubMedPubMedCentral

14.

Shorey RC, Gawrysiak MJ, Elmquist J, et al. Experiential avoidance, distress tolerance, and substance use cravings among adults in residential treatment for substance use disorders. Journal of Addictive Diseases 2017;36(3):151-157. https://doi.org/10.1080/10550887.2017.1302661CrossRefPubMedPubMedCentral

15.

Cyders MA, Dzemidzic M, Eiler WJ, et al. Negative urgency and ventromedial prefrontal cortex responses to alcohol cues: fMRI evidence of emotion-based impulsivity. Alcoholism: Clinical and Experimental Research 2013;38(2):409-417. https://doi.org/10.1111/acer.12266CrossRefPubMed

16.

Albein-Urios N, Martinez-González JM, Lozano Ó, et al. Comparison of impulsivity and working memory in cocaine addiction and pathological gambling: Implications for cocaine-induced neurotoxicity. Drug and Alcohol Dependence 2012;126(1-2):1-6. https://doi.org/10.1016/j.drugalcdep.2012.03.008CrossRefPubMed

17.

Rounsaville BJ. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Archives of General Psychiatry 1982;39(2):161-166. https://doi.org/10.1001/archpsyc.1982.04290020027006CrossRefPubMed

18.

Berg JM, Latzman RD, Bliwise NG, et al. Parsing the heterogeneity of impulsivity: A meta-analytic review of the behavioral implications of the UPPS for psychopathology. Psychological Assessment 2015;27(4):1129-1146. https://doi.org/10.1037/pas0000111CrossRefPubMed

19.

Fouyssac M, Peña-Oliver Y, Puaud M, et al. Negative urgency exacerbates relapse to cocaine seeking after abstinence. Biological Psychiatry 2022;91(12):1051-1060. https://doi.org/10.1016/j.biopsych.2021.10.009CrossRefPubMed

20.

Fischer S, Smith GT, Annus A, et al. The relationship of neuroticism and urgency to negative consequences of alcohol use in women with bulimic symptoms. Personality and Individual Differences 2007;43(5):1199-1209. https://doi.org/10.1016/j.paid.2007.03.011CrossRef

21.

Kaiser AJ, Milich R, Lynam DR, et al. Negative urgency, distress tolerance, and substance abuse among college students. Addictive Behaviors 2012;37(10):1075-1083. https://doi.org/10.1016/j.addbeh.2012.04.017CrossRefPubMedPubMedCentral

22.

Boos FZ, Broetto N, Silvestrin RB. Psychopharmacology of drugs of abuse. In Andrade ALM, De Micheli D, Silva EAD, Lopes FM, Pinheiro BDO, Reichert RA (Eds.). Psychology of substance abuse psychology of substance abuse. Springer Cham, 2021, pp. 3-21. https://doi.org/10.1007/978-3-030-62106-3CrossRef

23.

Blevins CE, Stephens R, Abrantes AM. Motives for prescription stimulant misuse in a college sample: Characteristics of users, perception of risk, and consequences of use. Substance Use & Misuse 2016;52(5):555-561. https://doi.org/10.1080/10826084.2016.1245338CrossRef

24.

Norton GR, Rockman GE, Ediger J, et al. Anxiety sensitivity and drug choice in individuals seeking treatment for substance abuse. Behaviour Research and Therapy 1997;35(9):859-862. https://doi.org/10.1016/s0005-7967(97)00037-5CrossRefPubMed

25.

Cyders MA, Littlefield AK, Coffey S, et al. Examination of a short English version of the UPPS-P Impulsive Behavior Scale. Addictive Behaviors 2014;39(9):1372-1376. https://doi.org/10.1016/j.addbeh.2014.02.013CrossRefPubMedPubMedCentral

26.

Dugré JR, Giguére CÉ, Percie du Sert O, et al. The psychometric properties of a short UPPS-P Impulsive Behavior Scale among psychiatric patients evaluated in an emergency setting Frontiers in Psychiatry 2019;10:39. https://doi.org/10.3389/fpsyt.2019.00139CrossRef

27.

WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002;97(9):1183-1194. https://doi.org/10.1046/j.1360-0443.2002.00185.xCrossRef

28.

Knapp KS, Bunce SC, Brick TR, et al. Daily associations among craving, affect, and social interactions in the lives of patients during residential opioid use disorder treatment. Psychology of Addictive Behaviors 2021;35(5):609-620. https://doi.org/10.1037/adb0000612CrossRefPubMed

29.

Opozda-Suder S, Karteczka-Świętek K, Piasecka M. Psychometric properties and longitudinal measurement invariance of the drug craving scale: Modification of the Polish version of the Penn Alcohol Craving Scale (PACS). PloS One 2021;16(9), e0256018. https://doi.org/10.1371/journal.pone.0256018CrossRefPubMedPubMedCentral

30.

IBM Corp. IBM SPSS Statistics for Macintosh, Version 19. Armonk, NY: IBM Corp, 2010

31.

Swendsen J, Conway KP, Degenhardt L, et al. Socio-demographic risk factors for alcohol and drug dependence: the 10-year follow-up of the national comorbidity survey. Addiction 2009;104(8):1346-1355. https://doi.org/10.1111/j.1360-0443.2009.02622.xCrossRefPubMedPubMedCentral

32.

Caplehorn JRM, Dalton MYNS, Haldar F, et al. Methadone maintenance and addicts’ risk of fatal heroin overdose. Substance Use & Misuse 1996;31(2):177-196. https://doi.org/10.3109/10826089609045806CrossRef

33.

Barnett PG, Rodgers JH, Bloch DA. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction 2001;96(5):683-690. https://doi.org/10.1046/j.1360-0443.2001.9656834.xCrossRefPubMed

34.

Trochim WM, Donnelly JP. Research Methods Knowledge Base (Vol. 2). Cincinnati, OH: Atomic Dog Pub, 2001

35.

Cohen J. Statistical Power Analysis for the Behavioral Sciences 2nd Hillside, NJ: Lawrence Erlbaum Associates, 1988. https://doi.org/10.4324/9780203771587CrossRef

36.

Smith GT, Anderson KG. Personality and learning factors combine to create risk for adolescent problem drinking: A model and suggestions for intervention. In Monti PM, Colby SM, O'Leary TA (Eds.). Adolescents, alcohol, and substance abuse: Reaching teens through brief interventions. Guilford Press, 2001, pp. 109–141. https://doi.org/10.1176/appi.ajp.159.11.1958CrossRef

37.

Smith GT, Cyders MA. Integrating affect and impulsivity: The role of positive and negative urgency in substance use risk. Drug and Alcohol Dependence 2016;163 (Supplement 1):S3-S12. https://doi.org/10.1016/j.drugalcdep.2015.08.038CrossRefPubMedPubMedCentral

38.

Ling W. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry 1996;53(5):401-407. https://doi.org/10.1001/archpsyc.1996.01830050035005CrossRefPubMed

39.

Diana M. The dopamine hypothesis of drug addiction and its potential therapeutic value. Frontiers in Psychiatry 2011;2:64. https://doi.org/10.3389/fpsyt.2011.00064CrossRefPubMedPubMedCentral

40.

Wise RA. Action of drugs of abuse on brain reward systems. Pharmacology Biochemistry and Behavior 1980;13 (Supplement 1):213-223. https://doi.org/10.1016/s0091-3057(80)80033-5CrossRefPubMed

41.

Lembke A. Time to abandon the self-medication hypothesis in patients with psychiatric disorders. The American Journal of Drug and Alcohol Abuse 2012;38(6):524-529. https://doi.org/10.3109/00952990.2012.694532CrossRefPubMed

42.

Lynch TR, Chapman AL, Rosenthal MZ, et al. Mechanisms of change in dialectical behavior therapy: Theoretical and empirical observations. Journal of Clinical Psychology 2006;62(4):459-480. https://doi.org/10.1002/jclp.20243CrossRefPubMed

Titel: Negative Urgency Linked to Craving and Substance Use Among Adults on Buprenorphine or Methadone
verfasst von: Stefanie F. Gonçalves, MA
Alyssa M. Izquierdo, MA
Rebecca A. Bates, DNP, FNP-C, PMP
Angeela Acharya, MS
Holly Matto, PhD, LCSW-C
Siddhartha Sikdar, PhD
Publikationsdatum: 06.07.2023
Verlag: Springer US
Erschienen in: The Journal of Behavioral Health Services & Research / Ausgabe 1/2024
Print ISSN: 1094-3412
Elektronische ISSN: 1556-3308
DOI: https://doi.org/10.1007/s11414-023-09845-4

Findings from an Organizational Context Survey to Inform the Implementation of a Collaborative Care Study for Co-occurring Disorders

Open Access

A Mixed Methods Analysis of Southern HIV Service Organizations’ Implementation of Harm Reduction to Address the HIV and Opioid Syndemic

Impacts of the Affordable Care Act Medicaid Expansion on Mental Health Treatment Among Low-income Adults Across Racial/Ethnic Subgroups, 2010–2017

Living Core Values and Establishing Organizational DNA

Organizational Network Analysis of SAMHSA’s Technology Transfer Center (TTC) Network

Open Access

A Cost Model for a Low-Threshold Clinic Treating Opioid Use Disorder

Neu im Fachgebiet Psychiatrie

Schadet Schichtarbeit dem Gehirn?

17.04.2025
AAN-Jahrestagung 2025
Kongressbericht

Eine große Registerstudie bestätigt, dass Schichtarbeit mit einem erhöhten Risiko für psychische und neurologische Erkrankungen einhergeht, sowie mit einer Volumenabnahme in Gehirnarealen, die für Depression, Angst und kognitive Funktionen relevant sind.

Starke Menopausensymptome: ein Hinweis auf kognitive Veränderungen?

17.04.2025
Perimenopause
Nachrichten

Stärkere Beschwerden in der Perimenopause sind mit einer reduzierten kognitiven Funktion in den mittleren und späteren Lebensjahren assoziiert. Auch das Verhalten kann sich ändern, wie eine Studie zeigt. Beides steht womöglich für erhöhte Demenzgefährdung.

Obstruktive Schlafapnoe: Das steht abseits von CPAP auf dem Plan

17.04.2025
DGP 2025
Kongressbericht

Die obstruktive Schlafapnoe kann durch verschiedene Verfahren behandelt werden wie Lagetherapie und chirurgische Interventionen. Eine medikamentöse Therapie kommt zwar (noch) nicht infrage. Auf dem Pneumologie-Kongress wurden aber erste vielversprechende Ansätze präsentiert.

Was tun, wenn pneumologische Medikamente Psyche und Blutbild verändern?

17.04.2025
DGP 2025
Kongressbericht

Arzneimittel für Patienten mit Mukoviszidose oder pulmonaler arterieller Hypertonie wirken offenbar nicht nur auf die Lunge. Was es in der Praxis zu beachten gilt, wurde beim Pneumologie-Kongress erläutert.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Negative Urgency Linked to Craving and Substance Use Among Adults on Buprenorphine or Methadone

Abstract

Weitere Artikel der Ausgabe 1/2024

Findings from an Organizational Context Survey to Inform the Implementation of a Collaborative Care Study for Co-occurring Disorders

A Mixed Methods Analysis of Southern HIV Service Organizations’ Implementation of Harm Reduction to Address the HIV and Opioid Syndemic

Impacts of the Affordable Care Act Medicaid Expansion on Mental Health Treatment Among Low-income Adults Across Racial/Ethnic Subgroups, 2010–2017

Living Core Values and Establishing Organizational DNA

Organizational Network Analysis of SAMHSA’s Technology Transfer Center (TTC) Network

A Cost Model for a Low-Threshold Clinic Treating Opioid Use Disorder

Neu im Fachgebiet Psychiatrie

Schadet Schichtarbeit dem Gehirn?

Starke Menopausensymptome: ein Hinweis auf kognitive Veränderungen?

Obstruktive Schlafapnoe: Das steht abseits von CPAP auf dem Plan

Was tun, wenn pneumologische Medikamente Psyche und Blutbild verändern?

Update Psychiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten